TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05779020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (split virion, inactivated)
Description: Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan (dose 0.25ml and 0.50ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (split virion, inactivated)
Description: Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan (dose 0.25ml and 0.50ml)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage
Description: Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage/dose 0.50ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage
Description: Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage/dose 0.25ml
Study: NCT06558838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir-penciclovir cream
Description: Patients will treat their cold sore with active study drug based upon their randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abreva
Description: Patients will treat their cold sore with Abreva based upon their randomization
Study: NCT05705466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Navtemadlin Placebo
Description: Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
Study: NCT02432417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
Study: NCT05978375

Intervention type: PROCEDURE
Intervention: Posterior intra-articular distraction and fusion
Description: Using reduction using posterior intra-articular distraction and fusion technique.
Study: NCT06458452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Using Virtual Reality based serious gaming module for Advanced Cardiac Life Support
Description: Group VG will use Artificial Intelligence driven Voice Recognition as an interface for game control whereas Group CG will only use hand held Virtual Reality controllers as an interface for game control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Using Virtual Reality based serious gaming module for Advanced Cardiac Life Support
Description: Group VG will use Artificial Intelligence driven Voice Recognition as an interface for game control whereas Group CG will only use hand held Virtual Reality controllers as an interface for game control
Study: NCT04991662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metaraminol
Description: Infusion of metaraminol adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Infusion of Phenylephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Infusion of Norepinephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
Study: NCT05112562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized attentional bias modification training
Description: In intervention is designed to train participants to disengage attention from potent e-cigarette cues and is based on the well-established attention retraining paradigm for other psychopathologies.
Study: NCT05978375

Intervention type: PROCEDURE
Intervention: Anterior transoral release and posterior cantilever reduction and fusion
Description: Using anterior transoral release and posterior cantilever reduction and fusion technique.

Intervention type: PROCEDURE
Intervention: TARP
Description: Using TARP technique.
Study: NCT05901194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight \< or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
Study: NCT05112562

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo attention control training
Description: This control training is very similar to the intervention's overall task structure and stimuli. The only difference is that the this control program is designed to exert no systematic manipulation on the attention deployment pattern between the two stimulus categories, thereby yielding no significant impact on the level of attentional bas toward ENDS-related cues
Study: NCT06500117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eMind application
Description: learning phase accompanied by application for 8 weeks, then independent practical application phases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Visual Analogue Scale VAS (craving) and Mobile Application Rating Scale MARS-F

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: focus groupe
Description: Patients who so wish will be able to give us more detailed feedback on the application. The focus groups will be carried out between visit 3 and visit 4.
Study: NCT06443190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indigenous Patient Navigator Support
Description: See Arm Description
Study: NCT06191393

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aptitude Medical Systems Metrix COVID/Flu Test
Description: The Metrix COVID/Flu Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2, Influenza A, and Influenza B via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result, detection of the Flu A gene target will produce a positive Flu A result, and detection of the Flu B gene target will produce a positive Flu B result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
Study: NCT06128304

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Implementation strategies
Description: Core Implementation Strategies~1. Ongoing consultation~2. Educational meetings~3. Strengthen referral system~4. Prepare patients to be active participants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core+ Enhanced Implementation Strategies
Description: Includes all of the Core implementation strategies and adds:~5. Community engagement using Health Beginning Initiative Model~6. Smart Cards to facilitate patient engagement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core+ Enhanced Implementation Strategies
Description: Includes all of the Core implementation strategies and adds:~5. Community engagement using Health Beginning Initiative Model~6. Smart Cards to facilitate patient engagement
Study: NCT05171192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CMAP Plus LTP
Description: The LTP Plus CMAP intervention will be delivered for a period of 12 weeks, including 8 weekly sessions and 2 sessions fortnightly. First 6 sessions will be for a duration of 60-90 minutes and remaining 4 sessions will take approximately 50-60 minutes. All sessions will be delivered by female therapists trained in CMAP and LTP intervention.
Study: NCT06468995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys completion
Description: Completion of surveys: the Feasibility of Implementation Measure (FIM), the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), a Likert scale, the EQ-5D-5L questionnaire, the HIV/AIDS-Targeted Quality of Life (HAT-QoL) questionnaire and the HIV Treatment Satisfaction Questionnaire (HIVTSQ).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surveys completion
Description: Completion of surveys: the Feasibility of Implementation Measure (FIM), the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), a Likert scale, the EQ-5D-5L questionnaire, the HIV/AIDS-Targeted Quality of Life (HAT-QoL) questionnaire and the HIV Treatment Satisfaction Questionnaire (HIVTSQ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home administration of CAB+RPV
Description: Drug treatment and follow-up at home (home arm).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hospital administration of CAB+RPV
Description: Drug treatment and follow-up in hospital (hospital arm)
Study: NCT04801017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-101
Description: TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemisinin
Description: Herbal Supplement/ Purified extract from Artemisia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemisinin
Description: Herbal Supplement/ Purified extract from Artemisia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride injection
Study: NCT06068569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)
Description: Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed. 1st injection - component I, 2nd injection - component II.
Study: NCT05550051

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Awake nasal fiberoptic intubation
Description: Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Awake nasal fiberoptic intubation
Description: Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation
Study: NCT05483946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of compartment compressibility
Description: Application of the CPM#1 device for compartment compressibility ratio measurement - for each participant, a pre-defined number of measurements will be conducted per leg and forearm
Study: NCT05749081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidophilin tablets in combination with vonorazan dual therapy
Description: 2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with vonorazan dual therapy
Description: 2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
Study: NCT05630846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational MMRV(H)NS vaccine
Description: 1 dose of a measles, mumps, and rubella at release potency and VNS at high (H) potency vaccine administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational MM(H)RVNS vaccine
Description: 1 dose of a measles, rubella, and varicella at release potency and mumps at high (H) potency vaccine administered subcutaneously.
Study: NCT06096246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: The catheter ablation (with a CE \[Conformité Européenne\] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: DC Cardioversion
Description: DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
Study: NCT05630846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational M(L)M(L)R(L)V(L)NS vaccine
Description: 1 dose of measles, mumps, rubella, and varicella, all at low (L) potency vaccine administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed MMRV_Lot 1 and Lot 2 vaccine
Description: 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 1 or 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 2 vaccine administered subcutaneously.
Study: NCT06155201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: functional training
Description: Based on individual differences, children are provided with structural psychological behavioral therapy, including the implementation of aerobic exercise and executive skills training based on motivational quotient theory. Use brain imaging, brain functional imaging and neuromodulation technology to improve children's symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: functional training
Description: Based on individual differences, children are provided with structural psychological behavioral therapy, including the implementation of aerobic exercise and executive skills training based on motivational quotient theory. Use brain imaging, brain functional imaging and neuromodulation technology to improve children's symptoms.
Study: NCT05230056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PG
Description: Shoulder Digital therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CTRL
Description: Shoulder non-digital therapy
Study: NCT05322447

Intervention type: DRUG
Group type: OTHER
Intervention: L Carnitine ( low dose)
Description: will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine ( high dose)
Description: will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
Study: NCT04696809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered subcutaneously.
Study: NCT06096246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DC Cardioversion
Description: DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implantable loop recorder
Description: The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable loop recorder
Description: The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Femoral sheath insertion
Description: Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral sheath insertion
Description: Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
Study: NCT05649709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-VA dual therapy
Description: 1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H-VA dual therapy
Description: 1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
Study: NCT06335667

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI + Diagnostic TURBT
Description: mpMRI in addition to the TURBT surgical procedure
Study: NCT06170528

Intervention type: DEVICE
Group type: OTHER
Intervention: AURA_ALZ
Description: AURA_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.
Study: NCT05419765

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood withdrawn
Description: Peripheral blood will be withdrawn in order to measure haematic lipids (total cholesterol and fractions, triglycerides), total blood LAL activity, to perform genetic analysis and finally to evaluate lipase activity into the platelets.~Hepatic elastography will be also executed, in 100 patients, according to the presence/absence of the PNPLA3 variant, in order to weigh up the genetic predisposition on NAFLD development or progression

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood withdrawn
Description: Peripheral blood will be withdrawn in order to measure haematic lipids (total cholesterol and fractions, triglycerides), total blood LAL activity, to perform genetic analysis and finally to evaluate lipase activity into the platelets.~Hepatic elastography will be also executed, in 100 patients, according to the presence/absence of the PNPLA3 variant, in order to weigh up the genetic predisposition on NAFLD development or progression
Study: NCT05884671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulpiride 400 MG
Description: All participants will receive one single dose of 400mg sulpiride. None of the participants will receive repeated doses. In order for the fMRI data acquisition to coincide with the time-window of maximal drug effects represented by a combination of plasma kinetics and physiological effects we will administer the drug 90 minutes prior to fMRI data acquisition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will receive placebo during one of the sessions.
Study: NCT06155201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: functional training
Description: Based on individual differences, children are provided with structural psychological behavioral therapy, including the implementation of aerobic exercise and executive skills training based on motivational quotient theory. Use brain imaging, brain functional imaging and neuromodulation technology to improve children's symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: functional training
Description: Based on individual differences, children are provided with structural psychological behavioral therapy, including the implementation of aerobic exercise and executive skills training based on motivational quotient theory. Use brain imaging, brain functional imaging and neuromodulation technology to improve children's symptoms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Children with depressive disorders, anxiety disorders, autism spectrum disorders, and attention deficit hyperactivity disorder were recruited at presentation. Differential interventions and assessments were conducted during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Children with depressive disorders, anxiety disorders, autism spectrum disorders, and attention deficit hyperactivity disorder were recruited at presentation. Differential interventions and assessments were conducted during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Children with depressive disorders, anxiety disorders, autism spectrum disorders, and attention deficit hyperactivity disorder were recruited at presentation. Differential interventions and assessments were conducted during the study.
Study: NCT06023771

Intervention type: PROCEDURE
Intervention: Invasive intervention for acute pancreatitis
Description: Invasive interventions include drainage (endoscopic transmural drainage, imaging-guided percutaneous catheter drainage) and debridement (endoscopic debridement, videoscopic assisted retroperitoneal debridement, laparoscopic surgical debridement, open surgical debridement).
Study: NCT06027424

Intervention type: OTHER
Description: observational study, no intervention

Intervention type: OTHER
Description: observational study, no intervention
Study: NCT06155201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Children with depressive disorders, anxiety disorders, autism spectrum disorders, and attention deficit hyperactivity disorder were recruited at presentation. Differential interventions and assessments were conducted during the study.
Study: NCT06027424

Intervention type: OTHER
Description: observational study, no intervention
Study: NCT04699929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: YH001 will be administered intravenously over 60minutes every three weeks (Q3W) for up to 1 years .
Study: NCT04731727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Corneal cross linking achieved by combination of Riboflavin and ultraviolet light
Study: NCT04991246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antigenic tests (on saliva samples)
Description: SARS-CoV-2 screening tests: two massive antigenic tests campaigns (on salivary samples).